ストックスクリーナーアプリを入手
11.20
2.18%
-0.25
前日終値:
$11.45
開ける：
$11.47
24時間の取引高:
177.90K
Relative Volume:
0.46
時価総額：
$548.52M
収益：
$82.71M
当期純損益:
$-102.24M
株価収益率:
-3.0518
EPS:
-3.67
ネットキャッシュフロー:
$-76.57M
1週間 パフォーマンス:
-7.67%
1か月 パフォーマンス:
+20.56%
6か月 パフォーマンス:
-13.18%
1年 パフォーマンス:
-25.33%
1日の値動き範囲:
$11.05
$11.55
1週間の範囲:
$11.05
$12.37
52週間の値動き範囲:
$9.03
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
URGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
11.20 | 548.52M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-19 | 再開されました | Ladenburg Thalmann | Buy |
| 2024-08-22 | 開始されました | Guggenheim | Buy |
| 2023-02-08 | ダウングレード | Jefferies | Buy → Hold |
| 2022-04-27 | 開始されました | Berenberg | Buy |
| 2020-04-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-09 | 開始されました | National Securities | Neutral |
| 2019-05-30 | 開始されました | JP Morgan | Neutral |
| 2019-05-29 | 開始されました | Goldman | Neutral |
| 2019-01-29 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-08 | 再開されました | Jefferies | Buy |
| 2018-04-04 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-11-15 | 繰り返されました | Oppenheimer | Outperform |
| 2017-11-15 | ダウングレード | Raymond James | Outperform → Mkt Perform |
すべてを表示
Urogen Pharma Ltd (URGN) 最新ニュース
Earnings call transcript: UroGen Pharma Q4 2024 reports mixed results - Investing.com India
Bank of New York Mellon Corp Increases Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Transitional Cell Carcinoma Treatment Market Size in 7MM - openPR
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Analysts - Defense World
HC Wainwright Expects Reduced Earnings for UroGen Pharma - Defense World
(URGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Urogen pharma outlines $1B revenue potential for UGN-102 with June 2025 launch target - MSN
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strat - GuruFocus.com
UroGen Pharma (NASDAQ:URGN) Price Target Cut to $55.00 by Analysts at HC Wainwright - Defense World
UroGen Pharma stock target cut to $55 at H.C. Wainwright By Investing.com - Investing.com Australia
UroGen Pharma stock target cut to $36 at Raymond James By Investing.com - Investing.com Australia
UroGen Pharma stock target cut to $36 at Raymond James - Investing.com India
UroGen Pharma stock target cut to $55 at H.C. Wainwright - Investing.com India
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call Transcript - Insider Monkey
UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - Defense World
UroGen Pharma Reports Strong Pipeline Progress and Revenue Growth - TipRanks
UroGen Pharma Ltd. SEC 10-K Report - TradingView
Earnings call transcript: UroGen Pharma Q4 2024 reports mixed results By Investing.com - Investing.com South Africa
UroGen Pharma shares fall as Q4 results miss estimates By Investing.com - Investing.com South Africa
UroGen Pharma shares fall as Q4 results miss estimates - Investing.com India
Urogen Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Urogen Pharma reports wider-than-expected fourth-quarter loss -March 10, 2025 at 10:56 am EDT - Marketscreener.com
Oppenheimer & Co. Inc. Acquires Shares of 11,875 UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma earnings missed by $0.03, revenue fell short of estimates - Investing.com Australia
UroGen Pharma Posts Wider Loss In Q4Quick Facts - Nasdaq
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 - Joplin Globe
Rhumbline Advisers Has $546,000 Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
UroGen Pharma Ltd. to Host Earnings Call - ACCESS Newswire
UroGen Pharma (URGN) to Release Earnings on Thursday - Defense World
BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight - GlobeNewswire Inc.
How to Take Advantage of moves in (URGN) - Stock Traders Daily
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 - StockTitan
UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC Wainwright - Defense World
Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - Yahoo Finance UK
UroGen stock holds Buy rating, $64 target from H.C. Wainwright By Investing.com - Investing.com South Africa
UroGen stock holds Buy rating, $64 target from H.C. Wainwright - Investing.com
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference - BioSpace
Can UroGen's Next Move Transform Urothelial Cancer Treatment? Key Insights Coming at TD Cowen - StockTitan
10 Best Small-Cap Growth Stocks to Buy Now - Insider Monkey
UroGen acquires IconOVir’s oncolytic virus assets - Yahoo Finance
UroGen Pharma (NASDAQ:URGN) Coverage Initiated at LADENBURG THALM/SH SH - Defense World
UroGen Plots Expansion, Brings In A New Asset - Insights
Low-Gade Upper Tract Urothelial Cancer Market on Track for Major - openPR
UroGen acquires oncolytic virus, expands cancer treatment options By Investing.com - Investing.com Nigeria
Urogen Pharma Ltd (URGN) 財務データ
収益
当期純利益
現金流量
EPS
Urogen Pharma Ltd (URGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Smith Jason Drew | General Counsel |
Jan 31 '25 |
Sale |
11.14 |
7,379 |
82,202 |
26,468 |
| Schoenberg Mark | Chief Medical Officer |
Sep 09 '24 |
Sale |
13.08 |
859 |
11,236 |
145,091 |
| Smith Jason Drew | General Counsel |
Sep 09 '24 |
Sale |
13.08 |
1,521 |
19,895 |
25,226 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):